Related Experiment Video
Updated: Feb 14, 2026
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout, and
Ching-Tsai Lin1,2, I-Chieh Chen3,4, Yen-Ju Chen1,2,3
1Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Introduction:
This study aimed to investigate the interaction between the ABCG2 rs4148155 and SLC22A12 rs75786299 variants and their association with incident gout and nephrolithiasis in the Taiwanese population to better understand the genetic loci regulating hyperuricemia and their contribution to nephrolithiasis development.
Methods:
This retrospective case-control study involved 35,280 adults from the Taiwan Precise Medicine Initiative database. We examined the prevalence of gout and ultrasound confirmed nephrolithiasis as the primary and secondary outcome. Logistic regression models were used to explore the associations between genetic variants, serum uric acid levels, incident gout, and nephrolithiasis.
Results:
The frequencies of the rs4148155 variant and the rs75786299 variant were 63.2% and 3.7%, respectively. Among participants, 7,056 were gout, and 4,110 had nephrolithiasis. Multivariable odds ratios (ORs) for gout were 1.67 and 1.96 among rs4148155 and rs75786299 carriers, respectively (p = 0.01 and p < 0.001). For nephrolithiasis, the multivariable ORs were 1.1 and 1.11 for rs4148155 and rs75786299 carriers, respectively (p = 0.004 and p = 0.32). Sex-stratified analysis revealed an additive risk of gout and nephrolithiasis among carriers of these genetic variants, regardless of gender. Independent risk factors for nephrolithiasis included higher age, male gender, and the presence of gout, hypertension, and hyperlipidemia.
Conclusion:
The study highlights a significant association between the rs4148155, rs75786299 variants and the development of gout and nephrolithiasis, indicating an additive risk among carriers. These findings support precision healthcare approaches for individuals with risk genetic variants to target hyperuricemia, gout, and systemic comorbidities, ultimately preventing nephrolithiasis.
Related Concept Videos
00:59Hospitals-II
Nurses that work in...
01:28Hospitals-I
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:08Base-Catalyzed Aldol Addition Reaction
01:27Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...